249P - The metastases spectrum of neuroendocrine neoplasms in gastrointestinal tract. (249P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Neuroendocrine Cancers
Presenter wen Cai
Citation Annals of Oncology (2017) 28 (suppl_10): x57-x76. 10.1093/annonc/mdx660
Authors W. Cai, H. Hu
  • Department Of Medical Oncology, 2nd Affiliated Hospital of Zhejiang University University School of Medicine, 310009 - Hangzhou/CN



Researches on metastatic sites pattern and survival in site-specific metastases are limited for gastrointestinal tract neuroendocrine neoplasms (GI NENs). In This study, we aim to describe the metastases spectrum of neuroendocrine tumor in gastrointestinal tract.


16,342 gastrointestinal tract neuroendocrine neoplasms patients diagnosed between 2010 and 2014 were identified from SEER data base. Metastatic site distribution information was obtained. All of statistical analyses were performed using the Stata 12.0 (Stata Corporation, College Station, TX). The metastatic potential of different GI NENs was assessed. Survival in metastatic GI NENs was assessed by primary sites, histology and metastatic sites.


We found that liver was the most common site of metastasis (64.64% of patients with metastases), and the small intestine was the most common source of NENs metastases (56.81% of patients with metastases). The metastatic potential of NENs varied depending on the primary site. As for multiple metastasis, liver combined with lung metastasis (4.22% of patients with metastases) and liver combined with bone metastasis (3.18% of patients with metastases) were two kinds of most common multiple metastasis forms. NENs metastasis to liver had a high proportion of solitary metastasis (87.23%). While solitary lung metastasis just occupied 18.92% for all lung metastasis. The metastases spectrum of neuroendocrine tumor (NET) and neuroendocrine carcinomas (NEC) was similar. Different primary sites shared various survival in the same metastasis site. The 1-year survival rate for solitary liver metastasis was better than solitary bone metastasis (53.04% vs 34.38%) and solitary brain metastasis (53.04% vs 0%). While solitary lung metastasis shown a better 4-year survival rate than solitary liver, solitary bone and solitary brain metastasis (14.29% vs 9.38% vs 7.54% vs 0%).


Knowledge of metastases spectrum of NENs in gastrointestinal tract may help to guide pre-treatment evaluation of patients and provide epidemiological evidence to detect the probable primary sites for metastatic NENs. The survival analysis for different primary sites varies depending on metastasis site could help physicians to make decisions on follow up strategy.

Clinical trial identification

Legal entity responsible for the study

Hanguang Hu




All authors have declared no conflicts of interest.